glp-1 drugs for parkinson's disease Are we measuring the wrong primary outcome for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Popular obesity drug fails in

Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems

Belli, M

B., Asakawa T., Takeuchi K., and Christopher R

A study on whether and how the activation of GLP-1R affects proliferation and apoptosis of human pancreatic cancer cells has demonstrated that GLP-1RAs might activate cAMP in a GLP-1R-dependent manner, subsequently inhibiting the AKT and ERK1/2 signaling pathways, hence inhibiting the growth of transplanted tumors in vivo , as well as inducing apoptosis and inhibiting the proliferation of a human pancreatic cancer cell line in vitro ( 225)

Many participants lost an average percentage of their body weight similar to early-stage GLP-1 injection trials, which is why experts believe it may emerge as a major rival to injectable GLP-1 receptor agonists

Maybe these meds have been a nightmare and youre feeling more confused than ever